Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 3/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12366227 | 0.90 | TDP1 (0.40) | SRD5A2SRD5A1MCL1TDP1TTR | |
| SCHEMBL12366231 | 0.89 | SRD5A2 (0.41) | SRD5A2SRD5A1MCL1TDP1TTR | |
| SCHEMBL12366009 | 0.88 | SRD5A2 (0.40) | SRD5A2SRD5A1MCL1TDP1TTR | |
| SCHEMBL12366177 | 0.88 | TDP1 (0.39) | SRD5A2TDP1TTRTSHR | |
| SCHEMBL12366191 | 0.87 | SLC6A3 (0.46) | SRD5A2MCL1KDM4ENPC1RAB9A | |
| SCHEMBL12366276 | 0.86 | TDP1 (0.39) | SRD5A2SRD5A1MCL1TDP1TTR | |
| SCHEMBL12366031 | 0.86 | TDP1 (0.39) | SRD5A2SRD5A1MCL1TDP1TTR | |
| SCHEMBL12366174 | 0.86 | TDP1 (0.41) | SRD5A2SRD5A1MCL1TDP1TTR | |
| SCHEMBL2261400 | 0.84 | HTR2B (0.49) | — | |
| SCHEMBL12366205 | 0.82 | TDP1 (0.40) | MCL1TDP1TTRMRGPRX4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | SRD5A2 412/4885SRD5A1 247/4885MCL1 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.